1. Home
  2. APA vs ABVX Comparison

APA vs ABVX Comparison

Compare APA & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo APA Corporation

APA

APA Corporation

HOLD

Current Price

$31.62

Market Cap

9.7B

Sector

Energy

ML Signal

HOLD

Logo Abivax SA American

ABVX

Abivax SA American

HOLD

Current Price

$113.31

Market Cap

10.5B

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
APA
ABVX
Founded
1954
2013
Country
United States
France
Employees
N/A
67
Industry
Oil & Gas Production
Sector
Energy
Exchange
Nasdaq
Nasdaq
Market Cap
9.7B
10.5B
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
APA
ABVX
Price
$31.62
$113.31
Analyst Decision
Hold
Buy
Analyst Count
20
12
Target Price
$25.21
$128.42
AVG Volume (30 Days)
6.4M
688.8K
Earning Date
05-25-2026
01-01-0001
Dividend Yield
3.29%
N/A
EPS Growth
75.77
N/A
EPS
3.99
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$7.33
$0.22
P/E Ratio
$7.57
N/A
Revenue Growth
N/A
N/A
52 Week Low
$13.58
$4.77
52 Week High
$30.31
$148.83

Technical Indicators

Market Signals
Indicator
APA
ABVX
Relative Strength Index (RSI) 70.31 40.38
Support Level $22.73 $107.99
Resistance Level N/A $131.27
Average True Range (ATR) 1.28 4.89
MACD 0.23 -0.83
Stochastic Oscillator 81.11 9.65

Price Performance

Historical Comparison
APA
ABVX

About APA APA Corporation

APA Corp is an independent exploration and production company. It develops, and produces crude oil, natural gas, and natural gas liquids. The Company's business has oil and gas operations in three geographic areas: the United States (U.S.), Egypt, and offshore the U.K. in the North Sea (North Sea). APA also has active development, exploration, and appraisal operations ongoing in Suriname, as well as exploration interests in Uruguay, Alaska, and other international locations.

About ABVX Abivax SA American

Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.

Share on Social Networks: